Jinlyu Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinlyu Sun has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Xiaohong Lyu
Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
4 shared publications- Hong Li
Peking Union Medical College Hospital
2 shared publications Hongna Li
Pulmonary and Critical Care Medicine, Binzhou People’s Hospital, Binzhou, China
2 shared publicationsRui Tang
State Key Laboratory of Complex Severe and Rare Diseases, Allergy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications- Rui Tang
Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
2 shared publications Shandong Wu
Hangzhou Zheda Dixun Biological Gene Engineering Co.,Ltd., Hangzhou, China
2 shared publications
Latest Publications
- 1 April 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1)
Management and Immunotherapy for Fungal Allergy: Clinical Practice and Unmet Needs
- 1 April 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1)
Management and Immunotherapy for Fungal Allergy: Clinical Practice and Unmet Needs
- Open Access
- 17 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1565972
Metabolomic insights into variable antihistamine responses in allergic rhinitis: unveiling biomarkers for precision treatment
Background: The clinical response to antihistamine therapy exhibits substantial heterogeneity among individuals with allergic rhinitis (AR). While these medications represent a cornerstone in AR management, the molecular basis underlying differential treatment outcomes remains incompletely understood. This investigation sought to delineate specific metabolomic profiles that distinguish between AR patients who demonstrate favorable responses to antihistamine treatment and those who exhibit therapeutic resistance.Methods: This investigation encompassed a cohort of 57 patients diagnosed with AR, stratified into antihistamine-effective (n=49) and antihistamine-ineffective (n=8) groups. The study protocol integrated multiple analytical approaches, including clinical phenotyping, serum vitamin D quantification, mRNA expression, and untargeted metabolomic analysis. Metabolomic profiling was conducted using a state-of-the-art liquid chromatography-mass spectrometry (LC-MS) platform, enabling comprehensive characterization of the serum metabolome.Results: While demographic characteristics and vitamin D levels showed no significant differences between two groups, blood H1R mRNA expression was significantly higher in antihistamine-ineffective patients (P=0.046), and nasal TPSB mRNA expression was elevated (P=0.006). Nineteen metabolites showed significant differences (p2.0, VIP>1.0) between groups. ROC curve analysis identified nine metabolites with high diagnostic potential (AUC>0.70), with Methotrexate (AUC=0.862), Pro-Val-Ala-Glu-Val (AUC=0.804), and TyrMe-Ile-OH (AUC=0.791) showing the strongest discriminatory power. Pathway analysis highlighted the involvement of caffeine metabolism and tryptophan metabolism pathways.Conclusions: This study identified distinct metabolomic signatures between antihistamine-effective and antihistamine-ineffective AR patients, providing potential biomarkers for predicting treatment response and new insights into the metabolic mechanisms underlying treatment efficacy in AR.
- 17 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1565972
Open AccessMetabolomic insights into variable antihistamine responses in allergic rhinitis: unveiling biomarkers for precision treatment
Background: The clinical response to antihistamine therapy exhibits substantial heterogeneity among individuals with allergic rhinitis (AR). While these medications represent a cornerstone in AR management, the molecular basis underlying differential treatment outcomes remains incompletely understood. This investigation sought to delineate specific metabolomic profiles that distinguish between AR patients who demonstrate favorable responses to antihistamine treatment and those who exhibit therapeutic resistance.Methods: This investigation encompassed a cohort of 57 patients diagnosed with AR, stratified into antihistamine-effective (n=49) and antihistamine-ineffective (n=8) groups. The study protocol integrated multiple analytical approaches, including clinical phenotyping, serum vitamin D quantification, mRNA expression, and untargeted metabolomic analysis. Metabolomic profiling was conducted using a state-of-the-art liquid chromatography-mass spectrometry (LC-MS) platform, enabling comprehensive characterization of the serum metabolome.Results: While demographic characteristics and vitamin D levels showed no significant differences between two groups, blood H1R mRNA expression was significantly higher in antihistamine-ineffective patients (P=0.046), and nasal TPSB mRNA expression was elevated (P=0.006). Nineteen metabolites showed significant differences (p2.0, VIP>1.0) between groups. ROC curve analysis identified nine metabolites with high diagnostic potential (AUC>0.70), with Methotrexate (AUC=0.862), Pro-Val-Ala-Glu-Val (AUC=0.804), and TyrMe-Ile-OH (AUC=0.791) showing the strongest discriminatory power. Pathway analysis highlighted the involvement of caffeine metabolism and tryptophan metabolism pathways.Conclusions: This study identified distinct metabolomic signatures between antihistamine-effective and antihistamine-ineffective AR patients, providing potential biomarkers for predicting treatment response and new insights into the metabolic mechanisms underlying treatment efficacy in AR.
- Open Access
- 10 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1555664
Distinct metabolomic signatures in allergic rhinitis with concurrent chronic spontaneous urticaria: an untargeted metabolomics analysis reveals novel biomarkers and pathway alterations
Background: Although allergic rhinitis (AR) and chronic spontaneous urticaria (CSU) share overlapping immunological pathways, their distinct clinical manifestations imply the involvement of unique underlying mechanisms. This study aimed to investigate the metabolomic differences between patients with AR alone and those with concurrent AR and CSU (AR_CSU, defined as patients simultaneously presenting with both conditions).Methods: An untargeted metabolomic analysis was performed on serum samples from 53 AR patients and 14 AR_CSU patients using ultra-performance liquid chromatography coupled with high-resolution mass spectrometry (LC-MS/MS). Multivariate statistical analyses, including partial least squares-discriminant analysis (PLS-DA) and orthogonal partial least squares-discriminant analysis (OPLS-DA), were employed to identify differential metabolites and metabolic pathways.Results: A total of 209 significantly different metabolites were identified between the AR and AR_CSU groups (p < 0.05). Distinct metabolic patterns were observed through PLS-DA and OPLS-DA analyses, with no overlap between the two groups. Twenty metabolites exhibited high diagnostic potential (AUC > 0.75), among which Fasciculic acid C and Biotin-XX-Hydrazide showed particularly strong discriminatory power (AUC ≈ 0.8). Pathway analysis highlighted significant alterations in linoleic acid, fatty acid, and arachidonic acid metabolism. Notably, fatty acid elongation pathways were upregulated in AR_CSU patients, whereas primary bile acid biosynthesis and Fc gamma R-mediated phagocytosis were downregulated.Conclusions: This study represents the first comprehensive metabolomic comparison between AR and AR_CSU, identifying distinct metabolic signatures and potential biomarkers. These findings advance our understanding of the pathophysiological differences between these conditions and could inform the development of targeted therapeutic strategies.
- 10 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1555664
Open AccessDistinct metabolomic signatures in allergic rhinitis with concurrent chronic spontaneous urticaria: an untargeted metabolomics analysis reveals novel biomarkers and pathway alterations
Background: Although allergic rhinitis (AR) and chronic spontaneous urticaria (CSU) share overlapping immunological pathways, their distinct clinical manifestations imply the involvement of unique underlying mechanisms. This study aimed to investigate the metabolomic differences between patients with AR alone and those with concurrent AR and CSU (AR_CSU, defined as patients simultaneously presenting with both conditions).Methods: An untargeted metabolomic analysis was performed on serum samples from 53 AR patients and 14 AR_CSU patients using ultra-performance liquid chromatography coupled with high-resolution mass spectrometry (LC-MS/MS). Multivariate statistical analyses, including partial least squares-discriminant analysis (PLS-DA) and orthogonal partial least squares-discriminant analysis (OPLS-DA), were employed to identify differential metabolites and metabolic pathways.Results: A total of 209 significantly different metabolites were identified between the AR and AR_CSU groups (p < 0.05). Distinct metabolic patterns were observed through PLS-DA and OPLS-DA analyses, with no overlap between the two groups. Twenty metabolites exhibited high diagnostic potential (AUC > 0.75), among which Fasciculic acid C and Biotin-XX-Hydrazide showed particularly strong discriminatory power (AUC ≈ 0.8). Pathway analysis highlighted significant alterations in linoleic acid, fatty acid, and arachidonic acid metabolism. Notably, fatty acid elongation pathways were upregulated in AR_CSU patients, whereas primary bile acid biosynthesis and Fc gamma R-mediated phagocytosis were downregulated.Conclusions: This study represents the first comprehensive metabolomic comparison between AR and AR_CSU, identifying distinct metabolic signatures and potential biomarkers. These findings advance our understanding of the pathophysiological differences between these conditions and could inform the development of targeted therapeutic strategies.
- Open Access
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (10) , 1215-1223
Genetic Polymorphisms of GP1BA, PEAR1, and PAI-1 may be Associated with Serum sIgE and Blood Eosinophil Levels in Chinese Patients with Allergic Diseases
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. Objective: This study aims to investigate the relationship between the serum specific Immunoglobulin E (sIgE), blood eosinophil, and the polymorphisms of glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and plasminogen activator inhibitor 1 gene (PAI-1) rs1799762. Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 283 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group. Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa =1, p < 0.001). The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms did not show different distribution between allergy patients and healthy individuals. Concerning allergy patients, the CT (n=33) genotype of GP1BA rs6065 had higher blood eosinophil level than the CC (n=250) genotype (0.59, IQR 0.32-0.72 vs 0.31, IQR 0.15-0.61, *109/L, p =0.005). The serum sIgE of AA (n=46) genotype of PEAR1 rs12041331 was lower (median 3.7, interquartile quartiles (IQR) 0.2-16.8, kU/L) than the GA (n=136) and GG (n=101) genotypes (GA median 16.3, IQR 3.1-46.3, kU/L, p = 0.002; GG median 12.9, IQR 3.0-46.9, kU/L, p =0.003). The GA genotypes of PEAR1 rs12041331were with higher blood eosinophil levels (median 0.42, IQR 0.17-0.74 *109/L) than the AA genotype (median 0.25, IQR 0.15-0.41*109/L, p =0.012). The sIgE of the 5G5G (n=44) genotype of PAI-1 rs1799762 was lower (median 5.0, IQR 0.1-22.8, kU/L) than the 4G5G (n=144) (median 17.3, IQR 3.7-46.0, kU/L, p = 0.012). Conclusion: The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of serum sIgE or blood eosinophil in Chinese allergic disease patients.
- 1 August 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (10) , 1215-1223
Open AccessGenetic Polymorphisms of GP1BA, PEAR1, and PAI-1 may be Associated with Serum sIgE and Blood Eosinophil Levels in Chinese Patients with Allergic Diseases
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. Objective: This study aims to investigate the relationship between the serum specific Immunoglobulin E (sIgE), blood eosinophil, and the polymorphisms of glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and plasminogen activator inhibitor 1 gene (PAI-1) rs1799762. Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 283 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group. Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa =1, p < 0.001). The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms did not show different distribution between allergy patients and healthy individuals. Concerning allergy patients, the CT (n=33) genotype of GP1BA rs6065 had higher blood eosinophil level than the CC (n=250) genotype (0.59, IQR 0.32-0.72 vs 0.31, IQR 0.15-0.61, *109/L, p =0.005). The serum sIgE of AA (n=46) genotype of PEAR1 rs12041331 was lower (median 3.7, interquartile quartiles (IQR) 0.2-16.8, kU/L) than the GA (n=136) and GG (n=101) genotypes (GA median 16.3, IQR 3.1-46.3, kU/L, p = 0.002; GG median 12.9, IQR 3.0-46.9, kU/L, p =0.003). The GA genotypes of PEAR1 rs12041331were with higher blood eosinophil levels (median 0.42, IQR 0.17-0.74 *109/L) than the AA genotype (median 0.25, IQR 0.15-0.41*109/L, p =0.012). The sIgE of the 5G5G (n=44) genotype of PAI-1 rs1799762 was lower (median 5.0, IQR 0.1-22.8, kU/L) than the 4G5G (n=144) (median 17.3, IQR 3.7-46.0, kU/L, p = 0.012). Conclusion: The GP1BA rs6065, PEAR1 rs12041331, and PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of serum sIgE or blood eosinophil in Chinese allergic disease patients.
- Open Access
- 25 February 2023
- Published by MDPI AG in Marine Drugs
- Vol. 21 (3) , 152
Structures and Anti-Allergic Activities of Natural Products from Marine Organisms
In recent years, allergic diseases have occurred frequently, affecting more than 20% of the global population. The current first-line treatment of anti-allergic drugs mainly includes topical corticosteroids, as well as adjuvant treatment of antihistamine drugs, which have adverse side effects and drug resistance after long-term use. Therefore, it is essential to find alternative anti-allergic agents from natural products. High pressure, low temperature, and low/lack of light lead to highly functionalized and diverse functional natural products in the marine environment. This review summarizes the information on anti-allergic secondary metabolites with a variety of chemical structures such as polyphenols, alkaloids, terpenoids, steroids, and peptides, obtained mainly from fungi, bacteria, macroalgae, sponges, mollusks, and fish. Molecular docking simulation is applied by MOE to further reveal the potential mechanism for some representative marine anti-allergic natural products to target the H1 receptor. This review may not only provide insight into information about the structures and anti-allergic activities of natural products from marine organisms but also provides a valuable reference for marine natural products with immunomodulatory activities.
- 25 February 2023
- Published by MDPI AG in Marine Drugs
- Vol. 21 (3) , 152
Open AccessStructures and Anti-Allergic Activities of Natural Products from Marine Organisms
In recent years, allergic diseases have occurred frequently, affecting more than 20% of the global population. The current first-line treatment of anti-allergic drugs mainly includes topical corticosteroids, as well as adjuvant treatment of antihistamine drugs, which have adverse side effects and drug resistance after long-term use. Therefore, it is essential to find alternative anti-allergic agents from natural products. High pressure, low temperature, and low/lack of light lead to highly functionalized and diverse functional natural products in the marine environment. This review summarizes the information on anti-allergic secondary metabolites with a variety of chemical structures such as polyphenols, alkaloids, terpenoids, steroids, and peptides, obtained mainly from fungi, bacteria, macroalgae, sponges, mollusks, and fish. Molecular docking simulation is applied by MOE to further reveal the potential mechanism for some representative marine anti-allergic natural products to target the H1 receptor. This review may not only provide insight into information about the structures and anti-allergic activities of natural products from marine organisms but also provides a valuable reference for marine natural products with immunomodulatory activities.
- Open Access
- 24 February 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1139813
The 4G/5G polymorphism of plasminogen activator inhibitor type 1 is a predictor of allergic cough
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. This study aims to investigate the relationship between the genetic susceptibility of Chinese patients with allergy disorders and the polymorphisms of plasminogen activator inhibitor 1 gene (PAI-1) rs1799762, cysteinyl leukotriene receptor 1 gene (CYSLTR1) rs320995, gasdermin B gene (GSDMB) rs7216389, glycoprotein IIIa gene (GPIIIa) rs5918, glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and tumor necrosis factor alpha gene (TNF-α) rs1800629.Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 286 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group.Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa = 1, p < .001). Only the distribution of PAI-1 rs1799762 was different between patients with allergic cough and healthy people (χ2 = 7.48, p = .0238). With regard to cough patients, the 4G4G and 5G5G genotypes were more frequent (allergic cough vs. healthy individuals: 4G4G 57.9% vs. 26.7%; 5G5G 20.0% vs. 13.3%), but the 4G5G genotype was more frequent in healthy people (allergic cough vs. healthy individuals: 45.7% vs. 60.0%). The CYSLTR1 rs320995, GSDMB rs7216389, GPIIIa rs5918, GP1BA rs6065, PEAR1 rs12041331, and TNF-α rs1800629 polymorphisms, however, did not show any of such relationships.Conclusion: The PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of Chinese allergic disease patients with cough performance.
- 24 February 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1139813
Open AccessThe 4G/5G polymorphism of plasminogen activator inhibitor type 1 is a predictor of allergic cough
Background: It has been suggested that genetic factors may be substantially linked to allergy disorders. This study aims to investigate the relationship between the genetic susceptibility of Chinese patients with allergy disorders and the polymorphisms of plasminogen activator inhibitor 1 gene (PAI-1) rs1799762, cysteinyl leukotriene receptor 1 gene (CYSLTR1) rs320995, gasdermin B gene (GSDMB) rs7216389, glycoprotein IIIa gene (GPIIIa) rs5918, glycoprotein Ib alpha gene (GP1BA) rs6065, platelet endothelial aggregation receptor 1 gene (PEAR1) rs12041331, and tumor necrosis factor alpha gene (TNF-α) rs1800629.Methods: From the Peking Union Medical College Hospital, this study enrolled 60 healthy participants and 286 participants with allergic diseases. TaqMan-minor groove binder (MGB) quantitative polymerase chain reaction (qPCR) was used to examine the gene polymorphisms in each group.Results: The TaqMan-MGB qPCR results were completely consistent with the DNA sequencing results, according to other studies in this medical center (Kappa = 1, p < .001). Only the distribution of PAI-1 rs1799762 was different between patients with allergic cough and healthy people (χ2 = 7.48, p = .0238). With regard to cough patients, the 4G4G and 5G5G genotypes were more frequent (allergic cough vs. healthy individuals: 4G4G 57.9% vs. 26.7%; 5G5G 20.0% vs. 13.3%), but the 4G5G genotype was more frequent in healthy people (allergic cough vs. healthy individuals: 45.7% vs. 60.0%). The CYSLTR1 rs320995, GSDMB rs7216389, GPIIIa rs5918, GP1BA rs6065, PEAR1 rs12041331, and TNF-α rs1800629 polymorphisms, however, did not show any of such relationships.Conclusion: The PAI-1 rs1799762 polymorphisms may be associated with the genetic susceptibility of Chinese allergic disease patients with cough performance.